<DOC>
	<DOCNO>NCT02563691</DOCNO>
	<brief_summary>This study assess safety efficacy use stereotactic radiotherapy conjunction hormone therapy patient metastatic prostate cancer limit number metastatic tumour .</brief_summary>
	<brief_title>Stereotactic Radiotherapy Oligometastatic Prostate Cancer</brief_title>
	<detailed_description>Patients receive androgen deprivation therapy ( ADT ) minimum 1 year . After , intermittent hormone therapy approach take , ADT restart prostate specific antigen ( PSA ) reach minimum 10-15 ng/mL . Lupron 30 mg IM deliver every 4 month ADT . The prostate ( previously treat ) treat dose 35-40 Gy 5 fraction . All visible nodal metastasis treat dose 30-35 Gy 5 fraction . It likely nodal metastasis shrink significantly ( often completely ) ADT . In scenario , involve nodal region treat modest dose 25 Gy 5 fraction ( roughly equivalent dose 46 Gy 23 fraction assume α/β value 1.4 ) . Non-spine bone metastasis treat dose 30-40 Gy 5 fraction . Metastases brain , spine , lung , liver , adrenal treat accord establish stereotactic radiotherapy ( SRT ) policy Sunnybrook Odette Cancer Centre . Comprehensive SRT deliver within 3 month start ADT . During `` '' period ADT ( PSA rise 10-15 ng/mL ) , comprehensive SRT repeat new oligometastases become visible . One month initiation comprehensive SRT , patient contact assess acute toxicity . After completion radiotherapy disease site , patient follow every 3-4 month PSA test development castrate resistant prostate cancer . At time point , late toxicity quality life collect minimum 2 year . Computed tomography ( CT ) chest/abdo/pelvis +/- magnetic resonance imaging ( MRI ) previously irradiate body sit bone scan perform whenever PSA reach ≥ 10 ng/mL ( prior re-starting androgen deprivation therapy intermittent hormone therapy approach ) , minimum frequency per year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Able provide inform consent . ECOG performance status 01 . Histologic confirmation prostate adenocarcinoma . Stage IV disease , 5 metastatic tumour outside prostate pelvic lymph node . ≤ 3 tumour within give organ system ( e.g . 3 brain metastasis , 3 liver metastasis ) . All sit disease amenable stereotactic radiotherapy . Castrate resistant prostate cancer . Evidence spinal cord compression . Previous radiotherapy current cancer ( exception upfront management primary prostate tumour , brain metastasis ( e ) prior androgen deprivation therapy ) . Inability safely treat site visible disease . Prior malignancy within past 5 year , exclude nonmelanoma skin cancer , insitu cancer .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>